Q3 2024 Aptargroup Inc Earnings Call Transcript
Key Points
- AptarGroup Inc (ATR) reported a 2% core sales growth and a 6% increase in adjusted EPS to $1.49 per share for the third quarter.
- The pharma segment showed strong performance with 12% core sales growth, driven by demand for proprietary drug delivery systems.
- The closures segment returned to its long-term target range with a 4% core sales growth and improved margins due to cost reduction efforts.
- AptarGroup Inc (ATR) secured a contract from the US federal government to advance its ActivShield sterilization technology.
- The company completed a joint venture in China, enhancing its competitive edge with cost-effective pump manufacturing and a complete local supply chain.
- The beauty segment experienced a 6% decline in core sales, attributed to lower tooling sales and less favorable product mix.
- Injectables core sales decreased by 12% due to a difficult comparison with substantial service revenue in the prior year.
- The company noted a challenging macro environment for the beauty segment, with continued weakness in China.
- There is potential for lumpiness in royalty revenues, which could impact future financial stability.
- AptarGroup Inc (ATR) anticipates some seasonal inventory rightsizing in the beauty and cough and cold end markets, which may affect short-term sales.
Thank you all for your patience. Today's conference call with Aptar will be starting shortly.
Ladies and gentlemen, thank you all for standing by. Welcome to Aptar's 2024 third quarter conference call. (Operator Instructions)
Introducing today's conference call is Mrs. Mary Skafidas, Senior Vice President, Investor Relations and Communications. Please go ahead.
Good morning. Hello, everyone and thanks for being with us today. Our speakers on the call today are Stephan Tanda, President and CEO; and Bob Kuhn, Executive Vice President and CFO. Also joining us on the call today is Vanessa Kanu, our CFO designate. Our press release and accompanying slide deck have been posted on our website under the investor relations page.
During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure and the reconciliations are set forth in the press release.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
